Abstract
Aim:
To investigate a potential association between SNP rs10494366 in the neural nitric oxide synthase adaptor protein (NOS1AP) and efficacy of repaglinide (an insulin secretagogue) in newly diagnosed Shanghai Chinese type 2 diabetes patients.
Methods:
A total of 104 newly diagnosed type 2 diabetes patients (69 men, 35 women) were recruited and treated with repaglinide for 24 weeks. Anthropometric measurements, clinical laboratory tests were obtained at baseline and after 24-week treatment. Genotyping was performed by sequencing.
Results:
The baseline value of BMI, HOMA-IR, HOMA-B, and fasting insulin level were significantly different between GG, GT, and TT genotypes (P=0.024, 0.030, 0.005, and 0.007, respectively). Carriers of TT genotype were in significant insulin resistance at baseline. After 24-week repaglinide monotherapy, the Δ value of fasting insulin (P=0.019) and HOMA-IR (P=0.011) were significantly different. TT carriers had the least insulin resistance after treatment. The mixed model analysis showed that the variation had an interaction effect with repaglinide treatment only on HOMA-IR (P=0.013).
Conclusion:
A common variant in rs10494366 is associated with repaglinide monotherapy efficacy on insulin resistance in newly diagnosed Shanghai Chinese type 2 diabetes patients.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Becker ML, Aarnoudse AJ, Newton-Cheh C, Hofman A, Witteman JC, Uitterlinden AG, et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea. Pharmacogenet Genomics 2008; 18: 591–7.
Bredt DS . Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic Res 1999; 31: 577–96.
Nisoli E, Clementi E, Paolucci C, Cozzi V, Tonello C, Sciorati C, et al. Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 2003; 299: 896–9.
Duplain H, Burcelin R, Sartori C, Cook S, Egli M, Lepori M, et al. Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation 2001; 104: 342–5.
Chiang HT, Cheng WH, Lu PJ, Huang HN, Lo WC, Tseng YC, et al. Neuronal nitric oxide synthase activation is involved in insulin-mediated cardiovascular effects in the nucleus tractus solitarii of rats. Neuroscience 2009; 159: 727–34.
Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P . Nitric oxide release accounts for insulin's vascular effects in humans. J Clin Invest 1994; 94: 2511–5.
Turini P, Thalmann S, Jayet PY, Cook S, Mathieu C, Burcelin R, et al. Insulin resistance in mice lacking neuronal nitric oxide synthase is related to an alpha-adrenergic mechanism. Swiss Med Wkly 2007; 137: 700–4.
Lajoix AD, Reggio H, Chardes T, Peraldi-Roux S, Tribillac F, Roye M, et al. A neuronal isoform of nitric oxide synthase expressed in pancreatic beta-cells controls insulin secretion. Diabetes 2001; 50: 1311–23.
Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH . CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998; 20: 115–24.
Chu AY, Coresh J, Arking DE, Pankow JS, Tomaselli GF, Chakravarti A, et al. NOS1AP variant associated with incidence of type 2 diabetes in calcium channel blocker users in the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 2010; 53: 510–6.
Hu C, Wang C, Zhang R, Ng MC, Bao Y, So WY, et al. Association of genetic variants of NOS1AP with type 2 diabetes in a Chinese population. Diabetologia 2010; 53: 290–8.
Scheen AJ . Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007; 46: 93–108.
He YY, Zhang R, Shao XY, Hu C, Wang CR, Lu JX, et al. Association of KCNJ11 and ABCC8 genetic polymorphisms with response to repaglinide in Chinese diabetic patients. Acta Pharmacol Sin 2008; 29: 983–9.
Hu C, Wang C, Zhang R, Ma X, Wang J, Lu J, et al. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia 2009; 52: 1322–5.
Wigginton JE, Cutler DJ, Abecasis GR . A note on exact tests of Hardy-Weinberg equilibrium. Am J Hum Genet 2005; 76: 887–93.
Hollingdal M, Sturis J, Gall MA, Damsbo P, Pincus S, Veldhuis JD, et al. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Diabet Med 2005; 22: 1408–13.
Del Prato S, Tiengo A . The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus. Diabetes Metab Res Rev 2001; 17: 164–74.
Zhang MX, Ou H, Shen YH, Wang J, Coselli J, Wang XL . Regulation of endothelial nitric oxide synthase by small RNA. Proc Natl Acad Sci USA 2005; 102: 16967–72.
Sartori C, Scherrer U . Insulin, nitric oxide and the sympathetic nervous system: at the crossroads of metabolic and cardiovascular regulation. J Hypertens 1999; 17: 1517–25.
Scherrer U, Sartori C . Insulin as a vascular and sympathoexcitatory hormone: implications for blood pressure regulation, insulin sensitivity, and cardiovascular morbidity. Circulation 1997; 96: 4104–13.
Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD . Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994; 94: 1172–9.
Acknowledgements
This work was funded by the National Natural Science Foundation of China (30630061), National 973 Program (2006CB503901), National 863 Program (2006AA02A409), key project of Science and Technology Commission of Shanghai Municipality (01ZD002), major program of Shanghai Municipality for Basic Research (08dj1400601), Shanghai Key Laboratory of Diabetes Mellitus (08DZ2230220), National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (U01-DK58026 and R01-DK073490).
We appreciate all the patients participating in this research. We are grateful to the doctors and nurses who participated in this study. We appreciate Professor Ze-min YAO (University of Ottawa) a critical reading of the manuscript.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Qin, W., Zhang, R., Hu, C. et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese. Acta Pharmacol Sin 31, 450–454 (2010). https://doi.org/10.1038/aps.2010.25
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2010.25
Keywords
This article is cited by
-
Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care
The Pharmacogenomics Journal (2020)
-
Joint effects of diabetic-related genomic loci on the therapeutic efficacy of oral anti-diabetic drugs in Chinese type 2 diabetes patients
Scientific Reports (2016)
-
Serum uric acid levels are associated with polymorphisms in the SLC2A9, SF1, and GCKR genes in a Chinese population
Acta Pharmacologica Sinica (2014)
-
The Role of Pharmacogenetics in Drug Disposition and Response of Oral Glucose-Lowering Drugs
Clinical Pharmacokinetics (2013)
-
Individualized Therapy for Type 2 Diabetes
Molecular Diagnosis & Therapy (2012)
